LISATA THERAPEUTICS (LSTA) Company Report

Lisata Therapeutics and Qilu Pharmaceutical have mutually terminated their February 2021 Exclusive License and Collaboration Agreement for certepetide in the Greater China region.
This termination results in Lisata regaining full, exclusive rights to certepetide in Mainland China, Hong Kong, Macau, and Taiwan.
Qilu Pharmaceutical will complete and wind down its ongoing Phase 2 clinical study (NCT06261359) for certepetide in metastatic pancreatic ductal adenocarcinoma, with Lisata potentially negotiating to license the study data.
Lisata anticipates its projected capital will fund operations into the first quarter of 2027, covering anticipated data milestones from its ongoing clinical trials.

Jan 27, 2026, 1:00 PM

Press Release

Lisata Therapeutics Enters Term Sheet for Acquisition by Kuva Labs

LSTA

M&A

Takeover Bid

Lisata Therapeutics has entered into a binding term sheet to be acquired by Kuva Labs, Inc..
The acquisition offers Lisata stockholders $4.00 per share in cash through a tender offer.
Additionally, stockholders will receive two non-tradeable contingent value rights (CVRs), each valued at $1.00 per share, payable upon the achievement of specific milestones related to certepetide.
The cash offer represents an approximate 85% premium over Lisata's most recent closing stock price, and including both CVRs, an approximate 180% premium.
The term sheet and transaction have been unanimously approved by the boards of directors of Lisata and Kuva, with a definitive purchase agreement expected prior to February 27, 2026.

Jan 21, 2026, 1:58 PM

8-K

Lisata Therapeutics Reports Q3 2025 Financial Results and Provides Business Update

LSTA

Earnings

Guidance Update

New Projects/Investments

Lisata Therapeutics reported a net loss of $4.2 million for the third quarter of 2025, an improvement from $4.9 million in the prior year, with operating expenses decreasing by 17.3% to $4.4 million.
As of September 30, 2025, the company had $19 million in cash and cash equivalents, which are projected to support current operations into the first quarter of 2027.
The company provided updates on several sirtepotide clinical trials, with final data from the ASCEND and iLISTA trials anticipated in Q1 2026, and top-line data from the Bolster trial expected in Q4 2025. Preliminary data from the Sendafox trial's pancreatic cancer cohort showed a 50% R0 resection rate and a 60% two-year overall survival rate.
Lisata expanded its business development activities by forming a strategic alliance with GATC Health for AI drug discovery and entering a non-exclusive global license agreement with Catalent for sirtepotide's use in ADC technology. A new composition of matter patent for sirtepotide was issued in July 2025, extending protection until March 2040.
The company is preparing for a Phase 3 trial for sirtepotide, having reached an agreement with the FDA on key protocol aspects, and plans to seek licensees or partners to fund the significant capital required for this next phase.

Nov 6, 2025, 9:30 PM

Transcript

Lisata Therapeutics Reports Q3 2025 Financial Results and Business Update

LSTA

Earnings

Guidance Update

New Projects/Investments

Lisata Therapeutics reported Q3 2025 operating expenses of $4.4 million, a 17.3% decrease from Q3 2024, and net losses of $4.2 million.
The company extended its cash runway into the first quarter of 2027, holding approximately $19.0 million in cash and cash equivalents as of September 30, 2025.
A global license agreement was formed with Catalent for certepetide, potentially yielding over $10 million in milestone payments and revenue sharing.
Positive data from certepetide clinical studies, including ASCEND, iLSTA, and CENDIFOX trials, were reported, with final data for ASCEND and iLSTA anticipated in Q1 2026 and BOLSTER topline data expected in Q4 2025.

Nov 6, 2025, 9:10 PM

8-K

Lisada Therapeutics (LSTA) provides update on clinical progress, financial position, and strategic partnerships

LSTA

New Projects/Investments

Guidance Update

Lisada Therapeutics (LSTA) is a clinical-stage pharmaceutical company primarily focused on solid tumor cancer, with its lead product, sotepatide, demonstrating promising results in clinical trials.
The company reports a cash runway through early 2027 and holds over $20 million in cash on its balance sheet, with no debt.
Sotepatide has completed Phase 2B trials and is Phase 3 ready for metastatic pancreatic ductal adenocarcinoma (MPDAC), showing significant improvements in overall survival and complete responses in Phase 2B data.
Lisada has secured Fast Track and Orphan Drug designations for sotepatide in pancreatic cancer in the US and Europe, and has an FDA-approved Phase 3 design.
The company has established several strategic alliances, including a global license with Catalent and a license in Greater China with Chivu Pharmaceutical, and is actively seeking partners for further development.

Oct 20, 2025, 5:30 PM

Transcript

Lisata Therapeutics Provides Update on SERTEPATIDE Development and Financial Position

LSTA

New Projects/Investments

Guidance Update

Lisata Therapeutics (LSTA) is a clinical-stage pharmaceutical company focused on solid tumor cancers, with its lead product being SERTEPATIDE, a proprietary internalizing RGD cyclic peptide designed to enhance the efficacy of other anti-cancer agents.
The company has completed Phase 2B trials and is Phase 3-ready for metastatic pancreatic ductal adenocarcinoma, with clinical data showing significant improvements in overall survival and complete response rates.
Lisata Therapeutics holds Fast Track designation and Orphan Drug status in the U.S. and Europe for pancreatic cancer, among other indications, and possesses a strong intellectual property portfolio protecting its products through 2040.
The company reported a cash runway through early 2027, with over $20 million in cash on the balance sheet and is debt-free.
Strategic alliances include a recent global license with Catalent for ADCs in combination with SERTEPATIDE, and the company is actively seeking partners to complete Phase 3 development.

Oct 20, 2025, 5:30 PM

Transcript

Lisata Therapeutics Updates on Certepetide Clinical Development and Financial Position

LSTA

New Projects/Investments

Guidance Update

Certepetide, LSTA's proprietary iRGD cyclic peptide adjuvant, is designed to optimize solid tumor treatment by enhancing drug penetration, modifying the tumor microenvironment, and inhibiting metastasis.
In the ASCEND Phase 2b study for metastatic pancreatic ductal adenocarcinoma (mPDAC), Cohort A showed a median overall survival (mOS) of 12.68 months for Certepetide + SoC compared to 9.23 months for SoC alone, while Cohort B demonstrated a median progression-free survival (mPFS) of 7.46 months for Certepetide + SoC versus 5.29 months for SoC alone.
Certepetide has secured FDA Fast Track Designation for pancreatic cancer and Orphan Drug Designations for multiple indications, including pancreatic cancer, which provide regulatory benefits like accelerated approval and market exclusivity.
Lisata Therapeutics has an agreed-upon global Phase 3 study design with the FDA for Certepetide in first-line mPDAC, targeting 657 patients with overall survival as the primary endpoint.
As of June 30, 2025, Lisata Therapeutics held $22.0 million in cash and investments with no debt, projecting a cash runway into Q1 2027.

Oct 14, 2025, 8:02 PM

8-K

Lisata Therapeutics Enters Non-Exclusive License Agreement with Catalent

LSTA

New Projects/Investments

Lisata Therapeutics, Inc. (LSTA) entered into a worldwide Non-Exclusive License Agreement with Catalent, Inc. on October 8, 2025.
Under the agreement, Lisata granted Catalent non-exclusive rights to utilize its novel iRGD cyclic peptide, certepetide, as an antibody drug conjugate (ADC) payload within Catalent's SMARTag® ADC platform.
Lisata is eligible to receive up to $10.5 million in aggregate pre-determined development milestone payments, in addition to tiered revenue sharing on future sales and/or partnerships.
Catalent will assume full responsibility for all research, development, and commercialization costs associated with the licensed intellectual property.